Berg
Berg is a private Framingham, Massachusetts biotech using an AI-driven disease research platform to identify biomarkers, with Project Survival as its flagship initiative targeting early diagnosis of pancreatic cancer for healthcare and life sciences research customers.
- Company typePrivate
- Founded2006
- HeadquartersFramingham, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Berg does
Berg is a privately held biopharmaceutical and biotechnology company founded in 2006 and headquartered in Framingham, Massachusetts. It positions itself as an AI-driven disease research firm, operating what it describes as an AI-based disease research platform intended to accelerate the identification of clinically actionable biomarkers.
The company's flagship initiative is Project Survival, an AI-driven research program focused on improving the early diagnosis of pancreatic cancer through accelerated biomarker identification, with the stated aim of enabling earlier testing and treatment. The core differentiator is the application of proprietary AI methods to biomarker discovery in a disease area where late-stage detection drives low survival rates. Berg's customer base, as inferred from public materials, is oriented toward healthcare providers, research institutions, and biotech companies engaged in cancer research and diagnostics, though no paying customers or commercial contracts are disclosed.
Berg's revenue model is not publicly disclosed and no pricing, distribution, or go-to-market detail is available. The only documented external financial event is a 2021 $200,000 donation from the Alliance of Families Fighting Pancreatic Cancer (AFFPC) supporting Project Survival. With 1–10 employees and limited public-facing digital infrastructure (the corporate website currently displays a loader/verification screen), the company appears to be operating at a research-intensive, pre-commercial scale.
Berg firmographics
Firmographics- Name
- Berg
- Website
- https://berghealth.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Berg is a private Framingham, Massachusetts biotech using an AI-driven disease research platform to identify biomarkers, with Project Survival as its flagship initiative targeting early diagnosis of pancreatic cancer for healthcare and life sciences research customers.
- Ownership category
- akta.pro rank
Berg industry classification
Industry- Product category
- AI-driven Drug Discovery and Biomarker Identification
- NAICS
- Software Publishers (5132), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
- akta.pro secondary industries
- Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), Medical Imaging AI (HDAAAEAH)
Keywords
Where Berg is headquartered
LocationHeadquarters
- HQ city
- Framingham
- HQ country
- United States
- HQ region
- North America
Markets served
Berg business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Berg product offering
Product offeringCore offering
Berg is a pharmaceutical and biotechnology company that develops an AI-based disease research platform for identifying disease biomarkers, with its flagship Project Survival initiative focused on accelerating biomarker identification to enable earlier diagnosis, testing, and treatment of pancreatic cancer. The company provides these AI-driven research capabilities and associated biotechnology products to healthcare providers, research institutions, and biotech companies.
Product overview
Berg is a biotech company focusing on disease research using AI. The company operates as a single-platform approach centered on its AI-driven research capabilities, with Project Survival representing its flagship initiative targeting pancreatic cancer early diagnosis.
Differentiator
Problem solved
Functional benefit
Products and services
- Project Survival
Companies that use Berg
Customer profileSegments1 record
Ideal customer profiles1 record
Berg technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Berg partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights4 records
Berg competitors and assessment
Company assessmentDirect peers
- Tempus Labs: Tempus is a leading AI-driven precision medicine company that uses data and analytics to enable biomarker-driven diagnostics and therapy selection, primarily in oncology. It is directly comparable to BERG in applying AI/ML to biomarker discovery and clinical decision support for cancer, but at much greater scale and with broader disease coverage.
- PathAI: PathAI applies AI to pathology and biomarker analysis to improve diagnostic accuracy. It is a direct peer to BERG in using AI to identify clinically meaningful biomarkers and translate them into diagnostic products, though PathAI focuses more on tissue pathology.
- Owkin: Owkin uses AI on multimodal patient data to discover biomarkers and improve oncology drug development and diagnostics. Directly comparable to BERG in combining AI with real-world clinical data for biomarker discovery, especially in oncology.
Broad incumbents
- Recursion Pharmaceuticals: Recursion uses an AI-enabled drug discovery platform spanning multiple therapeutic areas. While broader in scope than BERG's biomarker focus, it is comparable as an AI-first biotech platform pursuing data-driven therapeutic and biomarker insights.
- Schrödinger: Schrödinger applies physics-based and AI computational platforms to molecular design and biomarker interpretation for pharma partners. Comparable to BERG as a computational/AI life sciences platform with biomarker and diagnostic adjacencies.
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading molecular diagnostics company that uses genomic profiling to identify cancer biomarkers and guide treatment. Comparable to BERG as an established biomarker-driven oncology diagnostics provider, with a much broader commercial footprint.
Emerging players
- Insitro: Insitro combines ML with high-throughput biology for drug discovery and biomarker identification. Comparable to BERG as an AI-platform biotech, though focused earlier on therapeutic discovery rather than diagnostics.
- BenevolentAI: BenevolentAI applies AI to biomedical knowledge graphs and patient data to identify novel targets and biomarkers. Relevant peer to BERG given its AI-driven disease research positioning, though more oriented toward drug target discovery than diagnostic biomarker panels.
- Lantern Pharma: Lantern Pharma is an AI-driven oncology company that uses its RADR platform to identify biomarkers and match patients to therapies. Highly comparable to BERG given its AI + biomarker focus in oncology, though it operates more in the therapeutics space.
- Notable Labs: Notable Labs uses an AI-enabled functional drug screening platform to identify effective treatments for cancer patients. Comparable to BERG as an AI-precision medicine company working at the intersection of biomarkers and oncology therapy selection.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Berg social profiles
Digital presenceBerg financial estimates
Financial estimateRevenue estimate
Valuation estimate
Berg leadership team
Management profileNumber of profiles
Profiles1 record
Berg funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Berg M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Berg
What does Berg do?
Berg is a pharmaceutical and biotechnology company that develops an AI-based disease research platform for identifying disease biomarkers, with its flagship Project Survival initiative focused on accelerating biomarker identification to enable earlier diagnosis, testing, and treatment of pancreatic cancer. The company provides these AI-driven research capabilities and associated biotechnology products to healthcare providers, research institutions, and biotech companies.
Is Berg a public or private company?
Berg is a private company. It is classified as unknown and is currently operating.
When was Berg founded?
Berg was founded in 2006. It employs 1 to 10 people.
Where is Berg based?
Berg is headquartered in Framingham, United States, in the North America region.
Who are Berg's main competitors?
Direct peers on record are Tempus Labs, PathAI and Owkin. Broad incumbents are Recursion Pharmaceuticals, Schrödinger and Foundation Medicine. Emerging players are Insitro, BenevolentAI, Lantern Pharma and Notable Labs.
Does Berg have an API?
No public API is recorded for Berg.
What industry is Berg in?
Berg's product category is AI-driven Drug Discovery and Biomarker Identification. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 5132 and its SIC code is 7372.